New class of agents for treatment of hypertension...

New class of agents for treatment of hypertension: Focus on direct renin inhibition (>> click to go to the journal's website) Vascular Health and Risk Management, 10/13/10

Fogari R et al. – Aliskiren, the first orally active direct renin inhibitor, is an effective antihypertensive drug with distinctive characteristics, including good blockade of the renin–angiotensin system, a prolonged duration of action, pharmacologic effects that persist after drug discontinuation, and favorable tolerability comparable with placebo. The blood pressure–lowering effect of aliskiren monotherapy is similar, if not superior, to that of other first–line antihypertensive agents, and is greatly enhanced when aliskiren is combined with various other antihypertensive medications, without any adverse drug interactions. Aliskiren is also an effective and well tolerated therapy in special populations, including diabetic, obese, and elderly hypertensives. Beyond its blood pressure–lowering efficacy, results from experimental and clinical trials suggest that aliskiren has positive effects on markers of cardiovascular and renal damage. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Internal Medicine >> Click here to see the complete list Diagnosis and Treatment of Hypertension in Children Current Hypertension Reports, 09/28/10 Divergent Results Using Clinic and Ambulatory Blood Pressures : Report of a Darusentan-Resistant Hypertension Trial Hypertension, 10/07/10 Common Variants in the ATP2B1 Gene Are Associated With Susceptibility to Hypertension : The Japanese Millennium Genome Project Hypertension, 10/05/10

 

 

 

Cardiovascular risk factors and cognitive impairment (>> click to go to the journal's website) Sang Thrombose Vaisseaux, 10/13/10

Farid K et al. – Although age is the most important risk factor, cardiovascular risk factors and a history of cardiovascular disease are established as risk factors for cognitive decline and dementia. The preventive effect of antihypertensive treatment on cognitive decline is now well established but effects of treatment of dyslipidemia on reducing cognitive decline and dementia are inconclusive. Strategies for screening for vascular cognitive impairment are not standardized and long–term studies are needed to establish better prevention of cognitive vascular disorders. Receive more summaries like this by joining MDLinx. We provide free daily digests of top journal articles in your field. >> Click here to choose your specialties.

Other articles in Internal Medicine >> Click here to see the complete list Vitamin D and cardiovascular disease: Systematic review and meta-analysis of prospective studies Preventive Medicine, 09/29/10 The relationship between retinal arteriolar and venular calibers is genetically mediated and each is associated with risk of cardiovascular disease Investigative Ophthalmology and Visual Science, 10/12/10 Management of High Blood Pressure in Blacks : An Update of the International Society on Hypertension in Blacks Consensus Statement Hypertension, 10/05/10